Serum matrix metalloproteinase-3 in systemic sclerosis

Archives of Dermatological Research

Volumn 296, Issue 1, 2004, Pages 25-29

  Jinnin, Masatoshi ^a   Ihn, Hironobu ^a   Asano, Yoshihide ^a   Yamane, Kenichi ^a   Yazawa, Norihito ^a   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Arthralgia; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; PENICILLAMINE; RHEUMATOID FACTOR; STROMELYSIN;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS;

EID: 3042525240     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-004-0468-1     Document Type: Article

References (40)

1. Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22:130-140
2. LeRoy EC (1992) A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 51:3412-3419
3. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD (1995) Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 270:3423-3428
4. Kikuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K (1995) Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 33:973-978
5. Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, Kahari VM (1998) Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 110:416-421
6. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y (1994) Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 103:359-363
7. Murawaki Y, Ikuta Y, Kawasaki H (1999) Clinical usefulness of serum inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta 281:109-120
8. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38:969-975
9. Wu JJ, Lark MW, Chun LE, Eyre DR (1991) Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem 266:5625-5628
10. Obata K, Iwata K, Okada Y, Kohrin Y, Ohuchi E, Yoshida S, Shinmei M, Hayakawa T (1992) A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clin Chim Acta 211:59-72
11. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ (1987) Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 248:265-268
12. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI (1989) Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 86:2632-2636
13. Ogata Y, Enghild JJ, Nagase H (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267:3581-3584
14. Okada Y, Takeuchi N, Tomita K, Nakanishi I, Nagase H (1989) Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis 48:645-653
15. Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13:228-233
16. Subcommittee for Scleroderma Criteria of the ARA Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-589
17. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-206
18. 2-GPI) in systemic sclerosis. Clin Exp Immunol 37:1188-1192
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
20. Ihn H, Sato S, Tamaki T, Soma Y, Tsuchida T, Ishibashi Y, Takehara K (1992) Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res 284: 391-395
21. Otsuji S, Shibata H, Umeda M (1982) Turbidimetric immunoassay of serum C-reactive protein. Clin Chem 28:2121-2124
22. Ailus K, Melamies L, Tuomi T, Palosuo T, Aho K (1991) Measuring rheumatoid factor in nonrheumatoid subjects: immunoturbidimetric assay, latex slide test, and enzyme-linked immunosorbent assay compared. Clin Chem 37:1766-1769
23. Klein F, Janssens MB (1987) Standardization of serological tests for rheumatoid factor measurement. Ann Rheum Dis 46: 674-680
24. Gendi N, Gordon T, Tanner SB, Black CM (1992) The evolution of a case of overlap syndrome with systemic sclerosis, rheumatoid arthritis and systemic lupus erythematosus. Br J Rheumatol 31:783-786
25. Gendi NS, Welsh KI, Van Venrooij WJ, Vancheeswaran R, Gilroy J, Black CM (1995) HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 38: 259-266
26. Horiki T, Moriuchi J, Takaya M, Uchiyama M, Hoshina Y, Inada K, Inoko H, Tsuji K, Ichikawa Y (1996) The coexistence of systemic sclerosis and rheumatoid arthritis in five patients: clinical and immunogenetic features suggest a distinct entity. Arthritis Rheum 39:152-156
27. Zimmermann C, Steiner G, Skriner K, Hassfeld W, Petera P, Smolen JS (1998) The concurrence of rheumatoid arthritis and limited systemic sclerosis. Arthritis Rheum 41:1938-1945
28. Rodnan GP (1962) The nature of joint involvement in progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 56:422-439
29. Tuffanelli DL, Winkelmann RK (1961) Systemic scleroderma: a clinical study of 727 cases. Arch Dermatol 84:359-371
30. Aho K, Palosuo T, Knekt P, Alha P, Aromaa A, Heliövaara M (2000) Serum C-reactive protein does not predict rheumatoid arthritis. J Rheumatol 27:1136-1138
31. Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I (2002) The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 20:221-224
32. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161-166
33. Panat MJ, Williams AL, O'sullivan MM, Lewis PA, Coles EC, Jessop JD (2000) Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 43:1473-1477
34. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, Limburg PC (1994) Interrelationships of outcome measures and process variables in early rheumatoid arthritis - a comparison of radiological damage, physical disability, joint counts and acute phase reactions. J Rheumatol 21:425-429
35. Otterness IG (1994) The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 24:91-104
36. Williams RC Jr (1983) Symposium on the immunodiagnosis of rheumatic and related disease. Part II. Rheumatoid factors. Hum Pathol 14:386-391
37. Young A, van der Heijde D (1997) Can we predict aggressive disease? Baillieres Clin Rheumatol 11:27-48
38. Borghaei RC, Rawlings PL Jr, Mochan E (1998) Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum 41:1398-1406
39. Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP (2000) The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum 43:270-274
40. Morin I, Li WQ, Su S, Ahmad M, Zafarullah M (1999) Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetyl-cysteine in synovial fibroblasts. J Pharmacol Exp Ther 289: 1634-1640